A5066201212- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Medical Imaging Techniques and Applications
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Eosinophilic Disorders and Syndromes
- Childhood Cancer Survivors' Quality of Life
- Genetic factors in colorectal cancer
- Ovarian cancer diagnosis and treatment
- Hematopoietic Stem Cell Transplantation
- Frailty in Older Adults
- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Radiopharmaceutical Chemistry and Applications
- Chronic Myeloid Leukemia Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Kruppel-like factors research
- Cancer-related gene regulation
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Azienda Sanitaria Unità Locale di Reggio Emilia
2008-2025
ASL Roma
2025
Azienda USL di Bologna
2024
Ospedale Santa Maria
2003-2023
University of Modena and Reggio Emilia
1988-2023
Santa Maria Nuova Hospital
1995-2022
Weatherford College
2022
Tecnologie Avanzate (Italy)
2022
Federico II University Hospital
2014-2022
Starting from November 2001, 260 newly diagnosed patients with Hodgkin's lymphoma (HL) were consecutively enrolled in parallel Italian and Danish prospective trials to evaluate the prognostic role of an early interim 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan International Prognostic Score (IPS) advanced HL, treated conventional ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) therapy.Most (n = 190) presented disease (stages IIB through IVB), whereas...
The aim of the F2 study was to verify whether a prospective collection data would enable development more accurate prognostic index for follicular lymphoma (FL) by using parameters which could not be retrospectively studied before, and choosing progression-free survival (PFS) as principal end point.Between January 2003 May 2005, 1,093 patients with newly diagnosed FL were registered 942 individuals receiving antilymphoma therapy selected population. variables we used score definition means...
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients need reduced or more intensive treatments. Methods We performed a randomized trial to evaluate adaptation on the basis early PET (ePET) after two cycles doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) in previously untreated-according European Organisation...
To compare doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) versus etoposide, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) lomustine, vindesine, melphalan, prednisone, epidoxirubicin, bleomycin (COPPEBVCAD; CEC) for advanced Hodgkin's lymphoma (HL).Three hundred seven patients with HL (stage IIB, III, IV) were randomly assigned to receive six courses of ABVD, four escalated plus two standard BEACOPP, or CEC, a limited radiation therapy program.After median...
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult previously untreated stages II IV FL compare efficacy of eight doses R cycles cyclophosphamide, vincristine, prednisone (CVP) or six doxorubicin, (CHOP) fludarabine mitoxantrone (FM). The principal end point study...
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted prospective Elderly Project study on DLBCL than 64 years who underwent our Fondazione Italiana Linfomi original (oGA) (age, Cumulative Illness Rating Scale Geriatrics, activities daily living, instrumental living) before treatment. Treatment choice was left physician's...
Purpose Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral testis, CNS, and extranodal sites. To prevent these events, we designed an international phase II trial (International Extranodal Lymphoma Study Group 10 [IELSG-10]) that addressed feasibility activity of conventional chemoimmunotherapy associated CNS prophylaxis testis irradiation. The was conducted by the IELSG Italian Foundation. Patients Methods Fifty-three patients (age 22 to 79 years) untreated...
In this multicenter, prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone (Stanford V) procarbazine, prednisone, epidoxirubicin, lomustine, vindesine (MOPPEBVCAD), were compared with dacarbazine (ABVD) as standard therapy to select which regimen would best support a reduced radiotherapy program, was limited < or = sites either...
Summary This study investigated the clinical activity and toxicity of R‐HCVAD‐AM [rituximab plus HyperCVAD (R‐HCVAD) alternating with high‐dose cytarabine methotrexate (AM)] in patients newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70 years confirmed MCL received four cycles each R‐HCVAD AM. who obtained a partial response proceeded to autologous stem cell transplant. Sixty‐three were enrolled 60 fully eligible. Median age was 57 (22–66); 60%, 33% 7% classified at low (L)‐,...
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP doxorubicin, R-FM fludarabine mitoxantrone) regimens without rituximab maintenance as initial therapy for patients advanced-stage follicular lymphoma (FL). A previous analysis a median follow-up of 34 months showed superior 3-year time to treatment failure, the primary study end point, versus have better risk-benefit ratio in terms toxicity than R-FM. We report post hoc this...
Purpose The randomized HD2000 trial compared six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two standard BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, bleomycin; CEC) in patients with advanced-stage Hodgkin lymphoma. After a median follow-up 42 months, who received were reported to have experienced...
This multicenter, open-label, phase II study evaluated the combination of bendamustine, gemcitabine, and vinorelbine (BeGEV) as induction therapy before autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (HL).Patients HL who were to had after one previous chemotherapy line eligible. The primary end point was complete response (CR) rate four cycles therapy. Secondary points were: overall rate, mobilization activity, toxicity. Progression-free...
Summary COVID‐19 is associated with high mortality in patients haematological malignancies (HM) and rate of seroconversion unknown. The ITA‐HEMA‐COV project (NCT04352556) investigated patterns for SARS‐CoV‐2 IgG HMs. A total 237 patients, PCR‐positive at least one test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid 54 (22·8%) plasma cell neoplasms. Overall, 69% (164 237) detectable serum antibodies. Serologically negative (31%, 73...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. analysis of Early positron emission tomography (ePET) Response–Adapted Treatment localized Hodgkin Lymphoma H10...
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis irradiation eliminates recurrences reduces relapses. The IELSG30 phase 2 study investigated feasibility activity an intensified IT IV prophylaxis. Patients stage I/II PTL who had not received treatment cycles high-dose methotrexate (MTX) (1.5 g/m2) after 6 the R-CHOP regimen (rituximab,...